Leuprorelin depot - Camurus

Drug Profile

Leuprorelin depot - Camurus

Alternative Names: CAM 2032; Leuprolide Acetate FluidCrystal® Injection Depot; Prozenze

Latest Information Update: 22 Jun 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Camurus
  • Class Antineoplastics; Gonadotropins; Infertility therapies; Oligopeptides; Pituitary hormone releasing hormones
  • Mechanism of Action Gonadotropin releasing hormone stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Prostate cancer

Highest Development Phases

  • Phase II Prostate cancer

Most Recent Events

  • 22 Jun 2016 Leuprorelin depot - Camurus is available for licensing as of 21 Jun 2016. http://www.camurus.com/
  • 21 Jun 2016 Pharmacokinetics and adverse events data from a phase II clinical trial in Prostate cancer released by Camurus
  • 15 Mar 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top